Real relationship, real results
Potential side effects: Injection-site pain, redness, or allergic reactions are possible
These factors include systemic inflammation ( In concordance with the above, weight loss of a magnitude obtainable with bariatric surgery, or with newer agents such as semaglutide ( The reductions in ROS and systemic inflammation, in combination with improvements in the other cardiometabolic parameters, are also thought to mediate the substantiated but so far formally unconfirmed kidney-protective effects of GLP-1 RAs, which may also directly or indirectly carry a HF-related benefit, considering that CKD is a prominent risk factor for HF (Table 1), the results of which resembles our and another similar recent analysis ( Direct effects of GLP-1 receptor agonism on the heart is likely not a major contributor
And as demand continues to grow, what factors will determine whether patients can start and adhere to treatment long term
There's no standardized microdosing protocol yet that's part of why this conversation is still emerging